You just read:

Kyprolis® (Carfilzomib) Demonstrates Economic Value In Relapsed Or Refractory Multiple Myeloma Manuscript Published In "Journal of Medical Economics"

News provided by

Amgen

26 May, 2016, 16:00 ET